Append Medical

What Append Medical does

Append Medical is an Israeli medical device company founded in 2015 and headquartered in Or Yehuda that develops the Appligator™, a transcatheter Left Atrial Appendage (LAA) elimination system intended to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). The core technology is a vacuum-based catheter that inverts and ligates LAA tissue without leaving any permanent implant in the heart, thereby eliminating the two principal safety risks inherent to existing LAA occlusion devices — Device Related Thromboembolism (DRT), which raises stroke risk by approximately five-fold, and Peri Device Leakage (PDL), which raises it by approximately two-fold. The device is positioned as a universal-anatomy, faster-procedure alternative in an LAA occlusion market that is progressively replacing alternative stroke-prevention therapies for NVAF patients who are poor candidates for or cannot tolerate long-term anticoagulation.

The Appligator program is in first-in-human clinical evaluation after the FIH study began in March 2024, supported by a peer-reviewed preclinical publication in Science Direct. The company is led by CEO Nadav Agian with a lean executive team (CFO Yafit Keret, VP R&D Shay Raviv, VP RA/QA & Clinical Liz Zinger, CMO Dr. Haim Danenberg, Director of Operations Avi Hillel) and is governed by a board chaired by Shlomi Nachman (appointed April 2025) with representation from MEDX Xelerator and ALIVE Israel HealthTech Fund, alongside founder Zachi Berger. An advisory board of interventional cardiologists and electrophysiologists from Mount Sinai, Mayo Clinic, Cedars Sinai, Sheba Medical Center, CVC Frankfurt, and Medstar supports clinical strategy.

Append Medical is pre-revenue and pre-commercial. Its revenue model, once approvals are secured, is expected to be one-time device sales to hospitals and cardiac catheterization labs supplemented by training and clinical support services, with custom negotiated hospital pricing typical of the LAA occlusion category. To date the company has raised approximately $11.75 million across a 2021 Series A of $7.4 million (with Boston Scientific, Intellectual Ventures, and MEDX Xelerator) and a 2023 extended Series A of $4.35 million (with ALIVE Israel HealthTech Fund and Shoni Health Ventures). Go-to-market is intended to be a direct enterprise field sales motion targeting interventional cardiologists and electrophysiologists at major cardiac centers, supported by conference presence, scientific publication, and PR — consistent with an early clinical-stage medtech still building clinical evidence prior to broad commercialization.

Name

Append Medical

Legal name

Append Medical

Website

https://appendmedical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Append Medical is an Israeli clinical-stage medical device company developing the Appligator™, a transcatheter, implant-free vacuum system for Left Atrial Appendage elimination to prevent stroke in non-valvular atrial fibrillation patients who cannot tolerate anticoagulation.

Ownership category

akta.pro rank

Product category

Cardiac Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

akta.pro secondary industry

Auto-Injectors (Disposable & Reusable) (HLAHAIAB)

Keywords

• Cardiac medical devices
• Left atrial appendage closure
• Stroke prevention devices
• Transcatheter cardiac implants
• Atrial fibrillation therapy

Headquarters

HQ city

Or Yehuda

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. Medical Device Sales: One-time sale of the Appligator device to hospitals and cardiac centers for use in interventional procedures. Revenue would come from direct device sales to healthcare facilities upon regulatory approval and commercialization.
2. Professional Services: Training, support, and clinical services for medical staff using the Appligator system in catheterization labs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Append Medical develops the Appligator™, a transcatheter medical device designed to eliminate the Left Atrial Appendage (LAA) in patients with Non-Valvular Atrial Fibrillation (NVAF) as a stroke-prevention therapy. Unlike conventional implant-based LAA closure devices, the Appligator uses a vacuum-based catheter system to appose and weld the LAA tissue, eliminating the appendage without leaving a permanent implant. The company is advancing the device through First-in-Human clinical studies.

Product overview

Append Medical offers a single unified product: the Appligator™ (also referred to as the Append Transcatheter System). This is an implant-free transcatheter solution for left atrial appendage elimination designed to prevent stroke in patients with non-valvular atrial fibrillation. The device uses a proprietary vacuum system to invert and ligate LAA tissue, eliminating the need for permanent metallic implants that carry risks of device-related thromboembolism (DRT) and peri-device leakage (PDL).

Differentiator

Problem solved

Functional benefit

Products and services

• Appligator™ Transcatheter LAA Elimination System The Appligator™ is a transcatheter medical device that uses a vacuum-based catheter system to appose and weld the tissue of the Left Atrial Appendage (LAA), eliminating the appendage without leaving a permanent implant. It is intended for stroke prevention in patients with Non-Valvular Atrial Fibrillation (NVAF).

Quantifiable outcome

• Reduces stroke risk from Device Related Thromboembolism by eliminating the cause (no foreign material left in heart)
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic is a global med-device leader with structural-heart and cardiac-rhythm management franchises (including ablation and insertable cardiac monitors). It has previously evaluated and could re-enter the LAA occlusion space, making it both a broad incumbent competitor and a probable strategic acquirer of differentiated assets like the Appligator.
• Edwards Lifesciences: Edwards Lifesciences is a dominant structural-heart med-device incumbent (TAVR/surgical heart valves) with the clinical-trial infrastructure, KOL relationships, and capital to enter adjacent structural-heart categories including LAA occlusion. It represents both an indirect competitive threat and a likely strategic acquirer profile.

Emerging players

• JenaValve Technology: JenaValve is a clinical-stage structural-heart company developing transcatheter aortic and tricuspid valve repair/replacement devices. While not directly in LAA closure, it is a comparable early-to-mid-stage structural-heart med device sharing investor and strategic acquirer profiles with Append Medical.
• Cardiac Dimensions: Cardiac Dimensions develops the Carillon System, a transcatheter device for functional mitral regurgitation in heart-failure patients. It is a comparable structural-heart emerging player in the transcatheter interventional space, sharing clinical-trial-stage risk profile and strategic acquirer pool with Append Medical.

Regional players

• Lifetech Scientific: Lifetech Scientific (Shenzhen, China) markets the LAmbre LAA occluder, a transcatheter implant-based LAA closure device. It is a direct functional peer in LAA occlusion but primarily serves the Asia-Pacific region, making it a regional rather than head-to-head Western-market competitor.

Direct peers

• Boston Scientific: Boston Scientific's WATCHMAN is the dominant and most-established Left Atrial Appendage occlusion device, with a multi-billion-dollar franchise and the deepest clinical evidence base. It is the primary competitive incumbent that Append Medical's implant-free Appligator seeks to displace on safety grounds (DRT/PDL).
• Conformal Medical: Conformal Medical is developing the CLAAS System, a next-generation conformable LAA occluder designed to better seal varied LAA anatomies. Like Append, it is an emerging implant-based LAA occlusion competitor targeting the limitations of Watchman/Amulet, and would compete in the same physician and patient pool.
• Abbott: Abbott markets the Amplatzer Amulet (acquired via St. Jude Medical), the second major LAA occlusion device competing head-to-head with Watchman. As a broad structural-heart incumbent with global catheter-lab reach, Abbott is both a direct competitor and a potential strategic acquirer of an implant-free alternative.
• Occlutech: Occlutech offers the Occlutech LAA occluder, a transcatheter implant-based LAA closure device commercialized primarily in Europe and select international markets. It is a smaller-scale direct peer competing in the same procedural category and patient population as the Appligator.
• AtriCure: AtriCure markets the LARIAT epicardial LAA closure device and related atrial fibrillation surgical products, representing a non-implant alternative LAA closure approach. Although surgical rather than transcatheter, it addresses the same NVAF stroke-prevention use case and competes for the same cardiology referral pathways.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Append Medical